 Doxorubicin
"Doxorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
| Descriptor ID |
D004317
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200.175 D04.615.562.050.200.175 D09.408.051.059.200.175
|
| Concept/Terms |
Adriblastin- Adriblastin
- Adriblastine
- Adriblastina
- Adriablastine
- Adriablastin
DOXO-cell- DOXO-cell
- DOXO cell
- Urokit Doxo-cell
- Urokit Doxo cell
|
Below are MeSH descriptors whose meaning is more general than "Doxorubicin".
Below are MeSH descriptors whose meaning is more specific than "Doxorubicin".
This graph shows the total number of publications written about "Doxorubicin" by people in this website by year, and whether "Doxorubicin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 | | 1996 | 1 | 0 | 1 | | 1997 | 3 | 1 | 4 | | 1998 | 1 | 4 | 5 | | 1999 | 1 | 2 | 3 | | 2000 | 2 | 1 | 3 | | 2001 | 1 | 7 | 8 | | 2002 | 1 | 2 | 3 | | 2003 | 0 | 2 | 2 | | 2004 | 2 | 1 | 3 | | 2005 | 0 | 1 | 1 | | 2006 | 2 | 5 | 7 | | 2007 | 2 | 5 | 7 | | 2008 | 0 | 7 | 7 | | 2009 | 4 | 6 | 10 | | 2010 | 1 | 4 | 5 | | 2011 | 3 | 5 | 8 | | 2012 | 2 | 6 | 8 | | 2013 | 2 | 8 | 10 | | 2014 | 2 | 8 | 10 | | 2015 | 3 | 5 | 8 | | 2016 | 5 | 4 | 9 | | 2017 | 2 | 9 | 11 | | 2018 | 0 | 7 | 7 | | 2019 | 1 | 10 | 11 | | 2020 | 2 | 8 | 10 | | 2021 | 4 | 7 | 11 | | 2022 | 1 | 6 | 7 | | 2023 | 4 | 10 | 14 | | 2024 | 5 | 6 | 11 | | 2025 | 2 | 4 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Doxorubicin" by people in Profiles.
-
Guo Z, Ataran A, Ma P, Yu W, Hajirezaei H, Valenzuela Ripoll C, Pedersen LN, Rashidi O, Chan MM, Shen M, Kelley S, Sargazi A, Ozcan M, Lotfinaghsh A, Cho Y, Diab A, Grogan F, Klaas A, Pompian A, Imam A, Lodhi R, Zelleke AB, Kovacs A, Margulies KB, Szymanski J, Sardiello M, Razani B, Asnani A, Kopecky BJ, Signore PE, Yi BA, Basson CT, Ravichandran KS, Prabhu SD, Bergom C, Schilling JD, Lavine KJ, Javaheri A. Human Single-Nucleus RNA Sequencing Identifies CD47 as a Therapeutic Target for Doxorubicin-Induced Cardiomyopathy. Circulation. 2025 Sep 09; 152(10):661-681.
-
Venkatasubramanian R, Darrah MA, Mahoney SA, Hutton DA, Maurer GS, Ludwig KR, Van Dongen NS, Greenberg NT, Longtine AG, Brunt VE, Singh P, Galligan JJ, Trujillo MN, Kapahi P, Melov S, Rossman MJ, Seals DR, Clayton ZS. Cellular Senescence Mediates Doxorubicin Chemotherapy-Induced Aortic Stiffening: Role of Glycation Stress. Hypertension. 2025 Oct; 82(10):1767-1777.
-
Wilky BA, Julian KA, Maleddu A, Mailhot AC, Cartwright CR, Gao D, Moreno Tellez C, Kemp LE, Therrien NR, Chaudhry SS, Rytlewski JD, Brockman QR, Davila E, Elias AD. A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti-CTLA-4 Antibody) and Balstilimab (Anti-PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas. Clin Cancer Res. 2025 Jul 15; 31(14):2945-2956.
-
Li Y, Jacques S, Gaikwad H, Nebbia M, Banda NK, Holers VM, Tomlinson SA, Scheinman RI, Monte A, Saba L, Lasda E, Hasselberth J, Busquet N, Zelek WM, Moghimi SM, Simberg D. Enhanced immunocompatibility and hemocompatibility of nanomedicines across multiple species using complement pathway inhibitors. Sci Adv. 2025 Jul 11; 11(28):eadw1731.
-
Hernández-Benítez J, López-Azcarraga A, Flerlage JE, Castellino S, Aristizabal P, Hoppe BS, Milgrom SA, de Paula MJA, Mailhot Vega RB. Curative Treatment of Pediatric Hodgkin Lymphoma With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Consolidation Radiotherapy: A Systematic Review and Suggested Recommendations. JCO Glob Oncol. 2025 Jun; 11:e2400485.
-
Zhou X, Mould DR, Gore L, Bai X, Gupta N. Optimizing Brentuximab Vedotin Dosing in Pediatric Patients with Advanced Hodgkin Lymphoma: A Population Pharmacokinetic and Exposure-Response Analysis. Clin Pharmacol Ther. 2025 Jun; 117(6):1803-1810.
-
Tilden SG, Ricco MH, Hemann EA, Anchordoquy TJ. Exploiting a type III interferon response to improve chemotherapeutic safety and efficacy. Eur J Pharm Sci. 2025 Jan 01; 204:106974.
-
Xiang JJ, Campbell MT, Tu SM, Araujo J, Nieto Y, Lin JK, Xiao L, Shah AY, Wang J. Doxorubicin, Paclitaxel, and Cisplatin (ATP) for Relapsed/Refractory Germ Cell Tumors. Clin Genitourin Cancer. 2024 Dec; 22(6):102242.
-
Li Y, Saba L, Scheinman RI, Banda NK, Holers M, Monte A, Dylla L, Moghimi SM, Simberg D. Nanoparticle-Binding Immunoglobulins Predict Variable Complement Responses in Healthy and Diseased Cohorts. ACS Nano. 2024 10 22; 18(42):28649-28658.
-
Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky K, Elias AD, Vaklavas C, Beckwith H, Williams N, Arora M, Nangia C, Roussos Torres ET, Thomas B, Albain KS, Clark AS, Falkson C, Hershman DL, Isaacs C, Thomas A, Tseng J, Sanford A, Yeung K, Boles S, Chen YY, Huppert L, Jahan N, Parker C, Giridhar K, Howard FM, Blackwood MM, Sanft T, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Heditsian D, LeStage B, Perlmutter J, Pohlmann P, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|